Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ
Status:
Completed
Trial end date:
2014-08-28
Target enrollment:
Participant gender:
Summary
This randomized phase I/II trial studies the side effects and best dose of lapatinib
ditosylate and to see how well it works in treating patients with ductal breast carcinoma in
situ. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth.